Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ARVN Arvinas > Detailed Quotes

ARVN Arvinas

42.760
-1.730-3.89%
Trading Session 10/03 10:26 ET
High
45.180
Open
45.180
Turnover
2.55M
Low
42.510
Pre Close
44.490
Volume
58.33K
Market Cap
2.28B
P/E(TTM)
Loss
52wk High
97.330
Shares
53.21M
P/E(Static)
Loss
52wk Low
34.900
Float Cap
1.74B
Bid/Ask %
33.33%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
0.96
Historical Low
10.190
Dividend TTM
--
Div Yield TTM
--
P/B
3.39
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.14%
Amplitude
6.00%
Avg Price
43.766
Lot Size
1
Float Cap
1.74B
Bid/Ask %
33.33%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
0.96
Historical Low
10.190
Dividend TTM
--
P/B
3.39
Dividend LFY
--
Turnover Ratio
0.14%
Amplitude
6.00%
Avg Price
43.766
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...